Truist analyst Richard Newitter raised the firm’s price target on Medtronic (MDT) to $110 from $103 and keeps a Hold rating on the shares. The company’s PFA, or pulsed field ablation, driven revenue beat was accompanied an acceleration outlook for the CAS, Cardiac Ablation Solutions, segment, supporting a solid new product narrative heading into 2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT: